Skip to Content

Protopic (tacrolimus topical) Disease Interactions

There are 3 disease interactions with Protopic (tacrolimus topical):


Topical Calcineurin Inhibitors (Includes Protopic) ↔ Immunosuppression

Severe Potential Hazard, Moderate plausibility

Applies to: Immunodeficiency

The use of calcineurin inhibitors as pimecrolimus and tacrolimus topical should be avoided in immunocompromised adults and children, including patients on systemic immunosuppressive medications. Although causal relationship has not been established, there is a concern about a potential risk of infections, lymphomas and skin malignancies when using topical calcineurin inhibitors for a prolonged time.


Tacrolimus Topical (Includes Protopic) ↔ Renal Impairment

Moderate Potential Hazard, Moderate plausibility

Applies to: Renal Dysfunction

Rare postmarketing cases of acute renal failure have been reported in patients treated with topical tacrolimus. Systemic absorption is most likely to occur in patients with epidermal barrier defects, and when topical tacrolimus is applied to large body surface areas. Caution should be exercised in patients with history of renal impairment or predisposed to renal impairment.


Topical Calcineurin Inhibitors (Includes Protopic) ↔ Skin Malignancies

Moderate Potential Hazard, Moderate plausibility

Applies to: Skin Cancer

The use of calcineurin inhibitors such as pimecrolimus and tacrolimus topical should be avoided on malignant or premalignant skin conditions. Some of these conditions might present as dermatitis. Calcineurin inhibitors should also be avoided in any skin conditions where there is the potential for increased systemic absorption of the medication as when there is a skin barrier defect.

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.